EUVIMEDEUVIMED entdecken
Open Access

HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women

Jeanne Marrazzo, Li Tao, Marissa Becker, Ashley A Leech, Allan W Taylor, Faith Ussery, Michael Kiragu, Sushena Reza-Paul, Janet Myers, Linda-Gail Bekker, Juan Yang, Christoph Carter und 4 weitere

JAMA · 19.03.2024 · 331 (11) · 930

DOI: 10.1001/jama.2024.0464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 19.03.2024. Verfasst von Jeanne Marrazzo und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham School of Medicine, Birmingham. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, Sexual and Gender Minorities, Pre-Exposure Prophylaxis. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Emtricitabine and tenofovir disoproxil fumarate (F/TDF) for HIV preexposure prophylaxis (PrEP) is highly effective in cisgender men who have sex with men (MSM) when adherence is high (>4 doses/week). Real-world effectiveness and adherence with F/TDF for PrEP in cisgender women is less well characterized.

Objective

To characterize the effectiveness of F/TDF for PrEP and its relationship with adherence in cisgender women. Design, Setting, and Participants Data were pooled from 11 F/TDF PrEP postapproval studies conducted in 6 countries that included 6296 cisgender women aged 15 to 69 years conducted from 2012 to 2020. HIV incidence was evaluated according to adherence level measured objectively (tenofovir diphosphate concentration in dried blood spots or tenofovir concentration in plasma; n = 288) and subjectively (electronic pill cap monitoring, pill counts, self-report, and study-reported adherence scale; n = 2954) using group-based trajectory modeling. Exposures F/TDF prescribed orally once a day. HIV incidence was analyzed in subgroups based on adherence trajectory. Main Outcomes and Measures HIV incidence.

Results

Of the 6296 participants, 46% were from Kenya, 28% were from South Africa, 21% were from India, 2.9% were from Uganda, 1.6% were from Botswana, and 0.8% were from the US. The mean (SD) age at PrEP initiation across all studies was 25 (7) years, with 61% of participants being younger than 25 years. The overall HIV incidence was 0.72 per 100 person-years (95% CI, 0.51-1.01; 32 incident HIV diagnoses among 6296 participants). Four distinct groups of adherence trajectories were identified: consistently daily (7 doses/week), consistently high (4-6 doses/week), high but declining (from a mean of 4-6 doses/week and then declining), and consistently low (less than 2 doses/week). None of the 498 women with consistently daily adherence acquired HIV. Only 1 of the 658 women with consistently high adherence acquired HIV (incidence rate, 0.13/100 person-years [95% CI, 0.02-0.92]). The incidence rate was 0.49 per 100 person-years (95% CI, 0.22-1.08) in the high but declining adherence group (n = 1166) and 1.27 per 100 person-years (95% CI, 0.53-3.04) in the consistently low adherence group (n = 632). Conclusions and Relevance In a pooled analysis of 11 postapproval studies of F/TDF for PrEP among cisgender women, overall HIV incidence was 0.72 per 100 person-years; individuals with consistently daily or consistently high adherence (4-6 doses/week) to PrEP experienced very low HIV incidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsSexual and Gender MinoritiesPre-Exposure ProphylaxisMaleHumansFemaleTenofovirEmtricitabineHomosexuality, MaleCounseling

Substanzen

TenofovirEmtricitabineAnti-HIV Agents

Autor:innen und Institutionen

  • University of Alabama at Birmingham School of Medicine, Birmingham.
  • Now with National Institute of Allergy and Infectious Diseases, Rockville, Maryland.
  • Gilead Sciences, Inc, Foster City, California.
  • University of Manitoba, Winnipeg, Manitoba, Canada.
  • Vanderbilt University School of Medicine, Nashville, Tennessee.
  • US Centers for Disease Control and Prevention, Atlanta, Georgia.

Förderung

  • NIMH NIH HHS

Zitieren

APA

Marrazzo, J., Tao, L., Becker, M., Leech, A. A., Taylor, A. W., Ussery, F., Kiragu, M., Reza-Paul, S., Myers, J., Bekker, L. G., Yang, J., Carter, C., de Boer, M., Das, M., Baeten, J. M., & Celum, C. (2024). HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women. JAMA, 331(11), 930. https://doi.org/10.1001/jama.2024.0464

Vancouver

Marrazzo J, Tao L, Becker M, Leech AA, Taylor AW, Ussery F, et al. HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women. JAMA. 2024;331(11):930. doi:10.1001/jama.2024.0464

BibTeX
@article{Marrazzo2024,
  author = {Marrazzo, Jeanne and Tao, Li and Becker, Marissa and Leech, Ashley A and Taylor, Allan W and Ussery, Faith and Kiragu, Michael and Reza-Paul, Sushena and Myers, Janet and Bekker, Linda-Gail and Yang, Juan and Carter, Christoph and de Boer, Melanie and Das, Moupali and Baeten, Jared M and Celum, Connie},
  title = {HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women},
  journal = {JAMA},
  year = {2024},
  volume = {331},
  number = {11},
  pages = {930},
  doi = {10.1001/jama.2024.0464}
}
Kostenlos starten →